| 2022 | Dr. med. Thomas Graier, Graz Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis |
| 2021 | Dr.med.univ. Peter Kölblinger, Salzburg Adjuvant anti-PD-1 antibody treatment in stage III/IV melanoma: real-world experience and health economic considerations |
| Clemens Schöffl, BSc., Graz The crux of C1-INH testing in everyday lab work |
|
| 2020 | Dr. Christine Prodinger, Salzburg Profiling trial burden and patients‘ attitudes to improve clinical research in epidermolysis bullosa |
| Univ.-Doz. Dr. Benedikt Weber, Wien The frequency of photosensitizing drug dispensings in Austria and Germany: A correlation with their photosensitizing potential based on published literature |
|
